Exploring racial disparities and tumor characteristics of CA19-9 producer and non-producer among patients with advanced pancreatic ductal adenocarcinoma (PDAC): Implications for survival and personalized treatment strategies

被引：0
|
作者：
Omore, Ibrahim
Gandhi, Sonal
Wu, Linda
Cohen, Deirdre J.
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY USA
[2] Icahn Sch Med Mt Sinai Morningside West, New York, NY USA
[3] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16309
引用
收藏
页数：1
相关论文
共 2 条
  • [1] Association of CA19-9 and tumor size in treatment monitoring for patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
    Hahn, Andrew
    Travis, Bethnay
    Hunter, David
    Colorafi, Abbey
    Regan, Christina
    Bay, Curt
    Koo, Phillip
    Dragovich, Tomislav
    Choti, Michael A.
    Kundranda, Madappa N.
    Chang, John
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 693 - 693
  • [2] Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study
    Doppenberg, Deesje
    Stoop, Thomas F.
    van Dieren, Susan
    Katz, Matthew H. G.
    Janssen, Quisette P.
    Nasar, Naaz
    Prakash, Laura R.
    Theijse, Rutger T.
    Tzeng, Ching-Wei D.
    Wei, Alice C.
    Zureikat, Amer H.
    Groot Koerkamp, Bas
    Besselink, Marc G.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1919 - 1932
1